Plasma-Derived Exosomal miRNAs as Potentially Novel Biomarkers for Latent Autoimmune Diabetes in Adults
Quick Facts
- Publication title: Plasma-Derived Exosomal miRNAs as Potentially Novel Biomarkers for Latent Autoimmune Diabetes in Adults
- Journal: DIABETES RES CLIN PR
- Year: 2023
- DOI: 10.1016/j.diabres.2023.110570
- PMID/PMCID: 36746199
Research overview
To characterize the exosomal miRNA profiles of latent autoimmune diabetes in adults (LADA) and evaluate the biomarker potential of selected miRNAs to distinguish LADA from type 2 diabetes (T2D). This study uncovers the miRNA profiles of plasma-derived exosomes from LADA patients and identifies exosomal miRNAs as potential biomarkers to discriminate LADA from T2D for the first time.
Key findings
Seventy-five differentially expressed plasma-derived exosomal miRNAs were identified in LADA patients compared to healthy subjects.
The expression levels of three exosomal miRNAs (hsa-miR-146a-5p, hsa-miR-223-3p and hsa-miR-21-5p) were significantly different between the LADA group and the T2D group.
Study design
Plasma-derived exosomal miRNA expression profiles were measured in patients with LADA (N = 5) and control subjects (N = 5).
Five differentially expressed miRNAs were selected to validate their expression levels and assess their diagnostic potential by quantitative real-time PCR (qRT-PCR) in a larger cohort.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Plasma-Derived Exosomal miRNAs as Potentially Novel Biomarkers for Latent Autoimmune Diabetes in Adults Diabetes research and clinical practice. 2023. DOI: 10.1016/j.diabres.2023.110570. PMID/PMCID: 36746199.